# Utah Medical Products Inc: overview UTMD · Nasdaq · CIK 706698 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/utmd.md) · [Financials](/companies/utmd/financials.md) · [Filings](/companies/utmd/filings.md) · [Insiders](/companies/utmd/insiders.md) Latest reported revenue: [$8.5m](/filings/0001096906-26-001210.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001096906-26-001210). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.0](/filings/0001096906-26-000395.md) | [9.2](/filings/0001096906-26-000395.md) | [9.7](/filings/0001096906-26-000767.md) | [10.0](/filings/0001096906-26-001210.md) | [9.8](/filings/0001096906-26-000395.md) | [9.0](/filings/0001096906-26-000395.md) | [8.7](/filings/0001096906-26-000767.md) | [8.5](/filings/0001096906-26-001210.md) | | Gross margin | % | [58.0%](/filings/0001096906-26-000395.md) | [58.1%](/filings/0001096906-26-000395.md) | [57.0%](/filings/0001096906-26-000767.md) | [56.2%](/filings/0001096906-26-001210.md) | [57.1%](/filings/0001096906-26-000395.md) | [58.2%](/filings/0001096906-26-000395.md) | [60.6%](/filings/0001096906-26-000767.md) | [55.8%](/filings/0001096906-26-001210.md) | | Operating margin | % | [33.4%](/filings/0001096906-25-001839.md) | [32.0% d](/filings/0001096906-26-000395.md) | [32.5%](/filings/0001096906-26-000767.md) | [32.1%](/filings/0001096906-26-001210.md) | [26.6%](/filings/0001096906-25-001839.md) | [27.0% d](/filings/0001096906-26-000395.md) | [29.4%](/filings/0001096906-26-000767.md) | [31.1%](/filings/0001096906-26-001210.md) | | Net margin | % | [35.6%](/filings/0001096906-26-000395.md) | [31.7%](/filings/0001096906-26-000395.md) | [31.3%](/filings/0001096906-26-001210.md) | [30.6%](/filings/0001096906-26-001210.md) | [26.8%](/filings/0001096906-26-000395.md) | [28.4%](/filings/0001096906-26-000395.md) | [29.9%](/filings/0001096906-26-001210.md) | [31.5%](/filings/0001096906-26-001210.md) | | Diluted EPS | $ per share | [1.03](/filings/0001096906-26-000395.md) | [0.86](/filings/0001096906-26-000395.md) | [0.92](/filings/0001096906-26-000767.md) | [0.94](/filings/0001096906-26-001210.md) | [0.82](/filings/0001096906-26-000395.md) | [0.80](/filings/0001096906-26-000395.md) | [0.82](/filings/0001096906-26-000767.md) | [0.84](/filings/0001096906-26-001210.md) | | Free cash flow | $m | [3.8 d](/filings/0001096906-25-001839.md) | [2.9 d](/filings/0001096906-26-000395.md) | [4.3](/filings/0001096906-26-000767.md) | [2.8 d](/filings/0001096906-26-001210.md) | [3.9 d](/filings/0001096906-25-001839.md) | [3.4 d](/filings/0001096906-26-000395.md) | [3.0](/filings/0001096906-26-000767.md) | [1.2 d](/filings/0001096906-26-001210.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [49.1](/filings/0001811884-24-000009.md) | [52.3](/filings/0001096906-25-000308.md) | [50.2](/filings/0001096906-26-000395.md) | [40.9](/filings/0001096906-26-000395.md) | [38.5](/filings/0001096906-26-000395.md) | | Gross margin | % | [63.0%](/filings/0001811884-24-000009.md) | [61.6%](/filings/0001096906-25-000308.md) | [59.8%](/filings/0001096906-26-000395.md) | [59.0%](/filings/0001096906-26-000395.md) | [57.1%](/filings/0001096906-26-000395.md) | | Operating margin | % | [38.5%](/filings/0001811884-24-000009.md) | [37.9%](/filings/0001096906-25-000308.md) | [33.4%](/filings/0001096906-26-000395.md) | [33.2%](/filings/0001096906-26-000395.md) | [29.6%](/filings/0001096906-26-000395.md) | | Net margin | % | [30.1%](/filings/0001811884-24-000009.md) | [31.5%](/filings/0001096906-25-000308.md) | [33.1%](/filings/0001096906-26-000395.md) | [33.9%](/filings/0001096906-26-000395.md) | [29.3%](/filings/0001096906-26-000395.md) | | Diluted EPS | $ per share | [4.04](/filings/0001811884-24-000009.md) | [4.52](/filings/0001096906-25-000308.md) | [4.57](/filings/0001096906-26-000395.md) | [3.96](/filings/0001096906-26-000395.md) | [3.48](/filings/0001096906-26-000395.md) | | Free cash flow | $m | [20.7](/filings/0001811884-24-000009.md) | [20.3](/filings/0001096906-25-000308.md) | [21.6](/filings/0001096906-26-000395.md) | [14.6](/filings/0001096906-26-000395.md) | [14.3](/filings/0001096906-26-000395.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/utmd/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-29 | [Cornwell Kevin L](/insiders/1199423.md) | Chairman, CEO, Director, Officer | Purchase (P) | 1,000 | $66.75 | $66.8k | [Form 4](/filings/0001733614-26-000005.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BRANDES INVESTMENT PARTNERS, LP](/funds/1015079.md) | 2026-06-30 | $32.8m | 475,158 | | Added +25,879 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $14.1m | 203,690 | | Added +16,041 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $13.7m | 198,817 | | Added +909 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $12.1m | 175,814 | | Reduced −8,300 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $9.3m | 134,535 | | Reduced −4,025 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $7.5m | 108,048 | | Reduced −12,049 | | [Minerva Advisors LLC](/funds/1541536.md) | 2026-06-30 | $6.5m | 93,615 | | Unchanged | | [HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC](/funds/1164833.md) | 2026-06-30 | $5.9m | 85,231 | | Reduced −3,900 | | [RICE HALL JAMES & ASSOCIATES, LLC](/funds/1230765.md) | 2026-06-30 | $4.9m | 71,363 | | Added +3,481 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $4.8m | 69,671 | | Added +20,870 | ## Recent filings [All 542 filings](/companies/utmd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 15:10 ET | [8-K](/filings/0001096906-26-001602.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001096906-26-001602 | | 2026-08-31 | 13:33 ET | [8-K](/filings/0001096906-26-001326.md) | 7.01 Regulation FD disclosure | 0001096906-26-001326 | | 2026-08-12 | 13:57 ET | [10-Q](/filings/0001096906-26-001210.md) | Quarterly report, period 2026-06-30 | 0001096906-26-001210 | | 2026-07-23 | 15:13 ET | [8-K](/filings/0001096906-26-001112.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001096906-26-001112 | | 2026-05-12 | 15:52 ET | [10-Q](/filings/0001096906-26-000767.md) | Quarterly report, period 2026-03-31 | 0001096906-26-000767 | | 2026-05-04 | 15:09 ET | [8-K](/filings/0001096906-26-000685.md) | 5.07 Shareholder vote results | 0001096906-26-000685 | | 2026-04-23 | 15:49 ET | [8-K](/filings/0001096906-26-000602.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001096906-26-000602 | | 2026-04-02 | 16:59 ET | [DEF 14A](/filings/0001096906-26-000477.md) | Proxy statement, period 2026-04-02 | 0001096906-26-000477 | | 2026-03-27 | 17:23 ET | [10-K](/filings/0001096906-26-000395.md) | Annual report, period 2025-12-31 | 0001096906-26-000395 | | 2026-01-29 | 15:11 ET | [8-K](/filings/0001096906-26-000161.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001096906-26-000161 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001096906-26-000395.md), filed Mar 27, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 706698 - Tickers: UTMD - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: UT - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:47 ET. No prices; not investment advice.